Back
HFA Premium Access

Persistence to guideline-based therapy newly prescribed after a hospitalization for heart failure. Data from two large cohorts in the US and Germany.

Session: Chronic heart failure - pharmacotherapy 3
Topic: Pharmacotherapy
Speaker: Doctor A. Michel (Basel, CH)
Event: Heart Failure 2023

Congress Presentation

Add to my library

Like

About the speaker

Doctor Alexander Michel

Bayer AG, Basel (Switzerland)
0 follower

7 more presentations in this session

Benefits of empagliflozin in Hispanics and non-Hispanics with heart failure: a sub-analysis of the EMPEROR-trials

Speaker: Doctor M. Gamero (Philadelphia, US)

Access
Abstract
Slides
Like
Thumbnail

Real world data comparing HF guideline directed medical therapy before and after 2021 ESC HF guidelines.

Speaker: Mr M. Ferrari (Brescia, IT)

Access
Abstract
Slides
Like
Thumbnail

Prognostic impact of pharmacotherapy optimisation status in HFrEF patients using a contemporary measurement score

Speaker: Doctor A. Jordan (Mexico City, MX)

Access
Abstract
Slides
Like
Thumbnail

Beta-blockers and antiplatelet therapy in Takotsubo syndrome - To do or not to do?

Speaker: Doctor P. Rocha Carvalho (Vila Real, PT)

Access
Abstract
Slides
Like
Thumbnail

Hydrochlorothiazide for the treatment of acute volume overload worsening heart failure

Speaker: Associate Professor R. Rascon Sabido (Veracruz, MX)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Chronic heart failure - pharmacotherapy 3

Speakers: Doctor A. Michel, Doctor M. Gamero, Mr M. Ferrari, Doctor A. Jordan, Doctor P. Rocha Carvalho...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources